FDA Questions Benefit of Using GlaxoSmithKline's Avodart to Cut Prostate Cancer Risk

Wall Street Journal -- The Food and Drug Administration questioned the clinical benefit of using GlaxoSmithKline PLC's (GSK, GSK.LN) Avodart to cut the risk of prostate cancer. Avodart is currently approved to treat benign prostatic hypertrophy or an enlarged prostate. The company is seeking FDA approval to market the drug to certain men to reduce the risk of prostate cancer. The drug will be reviewed by an FDA advisory panel on Wednesday along with Merck & Co.'s (MRK) Proscar, a drug similar to Avodart.

Back to news